Smith & Nephew signs option on Helix BioMedix peptide:
This article was originally published in Clinica
Smith & Nephew has signed a memorandum of understanding with biotech peptide specialist, Helix BioMedix, under which the UK orthopaedics group has a right of first offer to license rights to various wound-related indications for one of the Bothell, Washington-based firm's peptides. Under such an arrangement, S&N would contribute its expertise in wound management to the development of the product as a topical anti-infective. The peptide, HB50, could be a useful tool in the fight against MRSA, among other pathogens.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.